News

APAS Technology Showcase Event
LBT Innovations Technology Showcase Event at our Adelaide offices on Thursday 28th November, with the Hon. David Ridgway, MP
2019 Australian Microcap Investment Conference
Today our managing director and CEO presented at the 2019 Australian Microcap Investment Conference
LBT wins at the Business SA Export Awards
LBT Innovations wins the 2019 Overall Winner for Product or Service Design at the Business SA 2019 Export Awards
First European Sale of APAS Independence
We are pleased to announce the first sale of an APAS® Independence instrument in the European Union to Labor Dr Wisplinghoff
LBT Innovations @ ExchangeSA
Today our managing director and CEO presented at the ExchangeSA 2019 listed companies conference in Adelaide
MRSA Analysis Module CE Mark Registration
We are pleased to announce that the Declaration of Conformity for the APAS® MRSA analysis module has been completed.
Finance News Network Interview with Brent Barnes
Brent Barnes, talks FY19 results and outlook and the adoption of our culture plate reading device APAS,, the sales process and regulatory approval.
ASX Small and Mid-Cap Conference 2019
LBT's CEO and Managing Director Brent Barnes presenting at the ASX Small and Mid-Cap Conference in Sydney on the 5th of September 2019
Proactive Investors Interview with Brent Barnes
Brent Barnes updates Proactive Investors on developments to forge ahead with product sales of its unique APAS Independence technology. 
LBT Presentation, FNN Investor Event
Our CEO presents on LBT's automated plate reading device for use in laboratories, regulatory clearance in the US and the size of the market opportunity.
APAS® INDEPENDENCE US FDA 510(k) CLEARANCE
A historic day as APAS Independence with Urine Analysis Module is available for sale in the United states providing access to over 1,500 potential customers.
Bioshares Analyst Report
LBT Innovations is resetting expectations with investors regarding the sale process for its automated plate processing instrument, called APAS Independence. Read the full report here.
MRSA Analysis Module – Clinical Study Commenced
We are pleased to announce that we have commenced a clinical study to validate clinical performance of APAS Independence’s automatic analysis of MRSA.
Breaking Into The US Market. What Does It Really Take? 
Our VP of Global Business Development Peter Bradley recently presented at the ANDHealth Digital Health Summit in Melbourne
Appointment US Based Non-Executive Director: Simon Arkell
LBT Innovations is pleased to announce the appointment of Simon Arkell as a Non-Executive Director, starting 30th January 2019.
FDA 510(k) submitted for APAS® Independence
LBT Innovations joint venture company, Clever Culture Systems submits US FDA 510(k) for APAS Independence instrument with Urine Analysis Module.